1. Home
  2. NOTE vs PLUR Comparison

NOTE vs PLUR Comparison

Compare NOTE & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

HOLD

Current Price

$1.22

Market Cap

24.7M

Sector

Technology

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$3.62

Market Cap

28.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOTE
PLUR
Founded
2013
2001
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.7M
28.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NOTE
PLUR
Price
$1.22
$3.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$29.25
$12.00
AVG Volume (30 Days)
261.7K
12.5K
Earning Date
03-12-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$102,673,000.00
$1,326,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
$0.60
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
121.74
52 Week Low
$1.00
$2.82
52 Week High
$24.36
$7.13

Technical Indicators

Market Signals
Indicator
NOTE
PLUR
Relative Strength Index (RSI) 38.59 64.21
Support Level $1.17 $3.30
Resistance Level $1.29 $3.90
Average True Range (ATR) 0.12 0.18
MACD 0.00 0.06
Stochastic Oscillator 33.08 92.75

Price Performance

Historical Comparison
NOTE
PLUR

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: